View Filing Data

Print Document View Excel Document

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2016	Oct. 28, 2016
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2016
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q3
Trading Symbol	CARA
Entity Registrant Name	Cara Therapeutics, Inc.
Entity Central Index Key	0001346830
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		27,282,863

Condensed Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 5,426	$ 15,101
Marketable securities	65,994	91,640
Income tax receivable	663	384
Other receivables	115	80
Prepaid expenses	4,820	1,729
Total current assets	77,018	108,934
Property and equipment, net	1,665	1,263
Restricted cash	1,469	700
Total assets	80,152	110,897
Current liabilities:
Accounts payable and accrued expenses	6,825	5,268
Total current liabilities	6,825	5,268
Deferred lease obligation	1,525	585
Commitments and contingencies (Note 14)
Stockholders' equity:
Preferred stock; $0.001 par value; 5,000,000 shares authorized at September 30, 2016 and December 31, 2015, zero shares issued and outstanding at September 30, 2016 and December 31, 2015.
Common stock; $0.001 par value; 100,000,000 shares authorized at September 30, 2016 and December 31, 2015, 27,282,863 shares and 27,254,863 shares issued and outstanding at September 30, 2016 and December 31, 2015, respectively.	27	27
Additional paid-in capital	211,954	209,943
Accumulated deficit	(140,199)	(104,891)
Accumulated other comprehensive income (loss)	20	(35)
Total stockholders' equity	71,802	105,044
Total liabilities and stockholders' equity	$ 80,152	$ 110,897

Condensed Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2016	Dec. 31, 2015
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	27,282,863	27,254,863
Common stock, shares outstanding	27,282,863	27,254,863

Condensed Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Revenue:
License and milestone fees		$ 1,710		$ 1,710
Collaborative revenue		730		2,093
Clinical compound revenue			$ 86
Total revenue		2,440	86	3,803
Operating expenses:
Research and development	$ 9,671	5,584	28,976	13,653
General and administrative	2,102	1,865	7,195	5,609
Total operating expenses	11,773	7,449	36,171	19,262
Operating loss	(11,773)	(5,009)	(36,085)	(15,459)
Other income	176	22	498	49
Loss before benefit from income taxes	(11,597)	(4,987)	(35,587)	(15,410)
Benefit from income taxes	55	200	279	250
Net loss	$ (11,542)	$ (4,787)	$ (35,308)	$ (15,160)
Net loss per share -Basic and Diluted	$ (0.42)	$ (0.19)	$ (1.29)	$ (0.64)
Weighted average shares:
Basic and Diluted	27,282,863	25,545,164	27,275,133	23,737,443
Other comprehensive loss, net of tax of $0:
Changes in unrealized gains (losses) on available-for-sale marketable securities	$ (21)		$ 55
Total comprehensive loss	$ (11,563)	$ (4,787)	$ (35,253)	$ (15,160)

Condensed Statements of Comprehensive Loss (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Income Statement [Abstract]
Other comprehensive income, tax	$ 0	$ 0	$ 0	$ 0

Condensed Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Follow On Public Offering [Member]	Common Stock [Member]	Common Stock [Member] Follow On Public Offering [Member]	Additional Paid-In Capital [Member]	Additional Paid-In Capital [Member] Follow On Public Offering [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Income (Loss) [Member]
Balance, Value at Dec. 31, 2014	$ 51,662		$ 23		$ 131,840		$ (80,201)
Balance, Shares at Dec. 31, 2014			22,802,039
Sale of common stock net of underwriting discounts and commissions and offering expenses, Value		$ 75,231		$ 4		$ 75,227
Sale of common stock, net of underwriting discounts and commissions and offering expenses, Shares				4,327,956
Stock-based compensation expense	1,807				1,807
Shares issued upon exercise of stock options, Value	323				323
Shares issued upon exercise of stock options, Shares			101,588
Net loss	(15,160)						(15,160)
Balance, Value at Sep. 30, 2015	113,863		$ 27		209,197		(95,361)
Balance, Shares at Sep. 30, 2015			27,231,583
Balance, Value at Dec. 31, 2015	105,044		$ 27		209,943		(104,891)	$ (35)
Balance, Shares at Dec. 31, 2015			27,254,863
Stock-based compensation expense	1,971				1,971
Shares issued upon exercise of stock options, Value	40				40
Shares issued upon exercise of stock options, Shares			28,000
Net loss	(35,308)						(35,308)
Other comprehensive income	55							55
Balance, Value at Sep. 30, 2016	$ 71,802		$ 27		$ 211,954		$ (140,199)	$ 20
Balance, Shares at Sep. 30, 2016			27,282,863

Condensed Statements of Stockholders' Equity (Parenthetical) - Follow On Public Offering [Member] $ in Thousands	9 Months Ended
	Sep. 30, 2015 USD ($) $ / shares
Underwriting discounts and commissions and offering expenses \| $	$ 5,269
Common Stock [Member]
Sale of common stock, per share \| $ / shares	$ 18.6

Condensed Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
Condensed Statements of Cash Flows - USD ($) $ in Thousands	Sep. 30, 2016	Sep. 30, 2015
Operating activities
Net loss	$ (35,308)	$ (15,160)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	1,971	1,807
Depreciation and amortization	1,346	580
Accretion/amortization on available-for-sale marketable securities	(183)
Realized gain on sales of marketable securities	(12)
Deferred rent costs	(158)	(214)
Changes in operating assets and liabilities:
Income tax receivable	(279)	(250)
Other receivables	(35)	(2,143)
Prepaid expenses	(3,091)	(1,649)
Accounts payable and accrued expenses	1,556	1,171
Deferred revenue		(1,452)
Net cash used in operating activities	(34,193)	(17,310)
Investing activities
Proceeds from maturities of available-for-sale marketable securities	59,650
Proceeds from sale of available-for-sale marketable securities	23,368
Purchases of available-for-sale marketable securities	(57,123)
Change in restricted cash	(769)
Purchases of property and equipment	(648)	(13)
Net cash provided by (used in) investing activities	24,478	(13)
Financing activities
Proceeds from follow-on offering of common stock, net of issuance costs		75,453
Proceeds from the exercise of stock options	40	323
Net cash provided by financing activities	40	75,776
Net cash (decrease) increase for the period	(9,675)	58,453
Cash and cash equivalents at beginning of period	15,101	52,663
Cash and cash equivalents at end of period	5,426	111,116
Noncash investing and financing activities
Tenant improvements paid by landlord	$ 1,094
Unpaid follow-on offering issuance costs		$ 222

Business

9 Months Ended

Sep. 30, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Business

1.	Business

Cara Therapeutics, Inc. (the “Company”, “we”, “our” or “us”) is a clinical-stage biopharmaceutical corporation formed on July 2, 2004. The Company is focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors. The Company’s primary activities to date have been organizing and staffing the company, developing its product candidates, including conducting preclinical studies and clinical trials of CR845-based product candidates and raising capital.

As of September 30, 2016, the Company has raised aggregate net proceeds of approximately $204,800 from several rounds of equity financing, including its initial public offering, which closed in February 2014 and its follow-on offering, which closed in August 2015, and the issuance of debt. In addition, the Company received approximately $32,500 under its license agreements for CR845, primarily with Maruishi Pharmaceutical Co. Ltd., or Maruishi, and Chong Kun Dang Pharmaceutical Corp., or CKD, and an earlier product candidate for which development efforts ceased in 2007 (see Note 10, Collaborations).

As of September 30, 2016, the Company had unrestricted cash and cash equivalents and marketable securities of $71,420 and an accumulated deficit of $140,199. The Company has incurred substantial net losses and negative cash flows from operating activities in nearly every fiscal period since inception and expects this trend to continue for the foreseeable future. The Company recognized net losses of $35,308 and $15,160 and had net cash used in operating activities of $34,193 and $17,310 for the nine months ended September 30, 2016 and 2015, respectively. The Company expects that cash and cash equivalents and marketable securities as of September 30, 2016 will be sufficient to fund its operations beyond one year.

The Company is subject to risks common to other life science companies including, but not limited to, uncertainty of product development and commercialization, lack of marketing and sales history, development by its competitors of new technological innovations, dependence on key personnel, market acceptance of products, product liability protection of proprietary technology, ability to raise additional financing, and compliance with Food and Drug Administration, or FDA, and other government regulations. If the Company does not successfully commercialize any of its product candidates, it will be unable to generate recurring product revenue or achieve profitability.

Basis of Presentation

9 Months Ended

Sep. 30, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Basis of Presentation

2.	Basis of Presentation

The unaudited interim condensed financial statements included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission, or the SEC. Accordingly, they do not include all information and disclosures necessary for a presentation of the Company’s financial position, results of operations and cash flows in conformity with generally accepted accounting principles in the United States of America, or GAAP. In the opinion of management, these unaudited interim financial statements reflect all adjustments, consisting primarily of normal recurring accruals, necessary for a fair presentation of results for the periods presented. The results of operations for interim periods are not necessarily indicative of the results for the full year. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from this report, as is permitted by SEC rules and regulations; however, the Company believes that the disclosures are adequate to make the information presented not misleading. The condensed balance sheet data for the year ended December 31, 2015 were derived from audited financial statements, but do not include all disclosures required by GAAP. These unaudited interim condensed financial statements should be read in conjunction with the audited financial statements and accompanying notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities, as of the date of the financial statements as well as the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from the Company’s estimates and assumptions. Significant estimates include the fair value of marketable securities that are classified as level 2 of the fair value hierarchy, useful lives of fixed assets, the periods over which certain revenues will be recognized, including licensing and collaborative revenue recognized from non-refundable up-front and milestone payments, the determination of prepaid research and development, or R&D, clinical costs and accrued research projects, the amount of non-cash compensation costs related to share-based payments to employees and non-employees and the periods over which those costs are expensed and the likelihood of realization of deferred tax assets.

Significant Accounting Policies

There have been no material changes to the significant accounting policies previously disclosed in Note 2 to the Financial Statements in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015.

Recent Accounting Pronouncements

In June 2016, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, No. 2016-13, Financial Instruments—Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments, or ASU 2016-13, which replaces the incurred loss impairment methodology in current GAAP, that delays recognition of a credit loss until it is probable that such loss has been incurred, with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. ASU 2016-13 modifies the other-than-temporary impairment model for available-for-sale debt securities by requiring (1) estimating expected credit losses only when the fair value is below the amortized cost of the asset; (2) recording a credit loss without regard to the length of time a security has been in an unrealized loss position; (3) limiting the measurement of the credit loss to the difference between the security’s amortized cost basis and its fair value and (4) presenting credit losses as an allowance rather than as a write-down, which will allow the Company to record reversals of credit losses in current period net income, a practice that is currently prohibited. ASU 2016-13 will be effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company is currently evaluating the effect that adoption of ASU 2016-13 will have on its results of operations, financial position and cash flows.

In May 2016, the FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients, or ASU 2016-12, which amends guidance in the new revenue standard, ASU No. 2014-09 Revenue from Contracts with Customers (Topic 606), or ASU 2014-09, on collectability, noncash consideration, presentation of sales tax and transition. The amendments in ASU 2016-12 are effective for annual reporting periods beginning after December 15, 2017 (i.e., January 1, 2018), including interim periods within those reporting periods, which is the same as for ASU 2014-09, as amended by ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, or ASU 2015-14. The Company is currently evaluating the effect that adoption of ASU 2016-12 will have on its financial statements.

In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606), Identifying Performance Obligations and Licensing, or ASU 2016-10, which clarifies the principle for determining whether a good or service is “separately identifiable” from other promises in the contract and, therefore, should be accounted for as a separate performance obligation. In that regard, ASU 2016-10 requires that an entity determine whether its promise is to transfer individual goods or services to the customer, or a combined item (or items) to which the individual goods and services are inputs. In addition, ASU 2016-10 categorizes intellectual property, or IP, into two categories: “functional” and “symbolic.” Functional IP has significant standalone functionality. All other IP is considered symbolic IP. Revenue from licenses of functional IP is generally recognized at a point in time, while revenue from licenses of symbolic IP is recognized over time. ASU 2016-10 has the same effective date and transition requirements as ASU 2014-09, as amended by ASU 2015-14. The Company is currently evaluating the effect that adoption of ASU 2016-10 will have on its financial statements.

In March 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606), Principal versus Agent Considerations (Reporting Revenue Gross versus Net), or ASU 2016-08, which clarifies the implementation guidance on principal versus agent considerations contained in ASU 2014-09 by specifying that the determination as to whether an entity that is involved in providing a good or a service to a customer is a principal or an agent is based upon whether the entity controls the good or the service before it is transferred to the customer. ASU 2016-08 has the same effective date and transition requirements as ASU 2014-09, as amended by ASU 2015-14. The Company is currently evaluating the effect that adoption of ASU 2016-08 will have on its financial statements.

In March 2016, the FASB issued ASU No. 2016-09, Improvements to Employee Share-Based Payment Accounting, or ASU 2016-09, which amends Accounting Standards Codification, or ASC, Topic 718, Compensation – Stock Compensation. ASU 2016-09 simplifies several aspects of the accounting for share-based payment transactions, including the accounting for forfeitures, income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years and early adoption is permitted. Certain of the amendments will be applied using a modified retrospective transition method by means of a cumulative-effect adjustment to equity as of the beginning of the period in which ASU 2016-09 is adopted, while other amendments will be applied retrospectively, prospectively or using either a prospective or a retrospective transition method. Upon adoption on January 1, 2017, the Company will account for forfeitures as they occur rather than estimate a forfeiture rate and will record a cumulative-effect adjustment in equity on the date of initial adoption. In periods subsequent to adoption, a higher expense will be recognized related to stock-based awards that are not forfeited. The Company expects that the income tax amendments within ASU 2016-09 will have no impact on its results of operations or cash flows because it is in a net operating loss position with a full valuation allowance.

In May 2014, the FASB issued ASU 2014-09, which changes the principle under which the Company will recognize revenue from contracts with customers from one which requires the Company to satisfy specific criteria before recognizing revenue to one which requires the Company to recognize revenue in an amount that reflects the consideration to which it expects to be entitled in exchange for the transfer of promised goods or services to customers. ASU 2014-09, as amended by ASU 2015-14, is effective for annual reporting periods beginning after December 15, 2017 (i.e., January 1, 2018), including interim periods within those reporting periods. The standard allows for two transition methods: (1) retrospectively to each prior reporting period presented, or (2) using a modified retrospective approach, with the cumulative effect of initially applying ASU 2014-09 recognized as an adjustment to the opening balance of retained earnings at the date of initial adoption. The Company is currently in the process of deciding which method of transition it will use and the effect of adoption of ASU 2014-09 on its results of operations, financial position and cash flows. The Company currently recognizes revenue only from contracts with Maruishi and CKD, under both of which the Company may earn future milestone payments upon the achievement of defined clinical and regulatory events. The Company is continuing to monitor the timing of achievement of such milestones. To the extent that all defined milestones have not been achieved and the related revenue recognized under current GAAP prior to the adoption of ASU 2014-09, those contracts will be included within the scope of ASU 2014-09. However, since the current accounting for those contracts, as multiple element arrangements with milestone revenue recognized using the milestone method, is similar to ASU 2014-09, the Company does not expect a material effect on its financial statements from the adoption of ASU 2014-09.

Available-for-Sale Marketable Securities

9 Months Ended

Sep. 30, 2016

Investments, Debt and Equity Securities [Abstract]

Available-for-Sale Marketable Securities

3.	Available-for-Sale Marketable Securities

As of September 30, 2016 and December 31, 2015, the Company’s available-for-sale marketable securities consisted of money market mutual funds and debt securities issued by the U.S. government and government-sponsored entities and by investment grade institutions.

The following tables summarize the Company’s available-for-sale marketable securities by major type of security as of September 30, 2016 and December 31, 2015:

As of September 30, 2016


			Gross Unrealized
Type of Security	Amortized Cost		Gains		Losses			Estimated Fair Value
Money market mutual funds	$	18,858	$	19	$	—		$	18,877
U.S. Treasury securities		2,501		1		—			2,502
U.S. government agency obligations		8,886		4		—			8,890
Corporate bonds		15,054		2		(5	)		15,051
Commercial paper		20,675		2		(3	)		20,674

Total available-for-sale marketable securities	$	65,974	$	28	$	(8	)	$	65,994

As of December 31, 2015


			Gross Unrealized
Type of Security	Amortized Cost		Gains		Losses			Estimated Fair Value
Money market mutual funds	$	42,017	$	—	$	(31	)	$	41,986
U.S. Treasury securities		2,528		—		—			2,528
U.S. government agency obligations		13,492		4		—			13,496
Corporate bonds		14,194		—		(6	)		14,188
Commercial paper		19,444		1		(3	)		19,442

Total available-for-sale marketable securities	$	91,675	$	5	$	(40	)	$	91,640

All available-for-sale marketable securities are classified in the Company’s Condensed Balance Sheets as Marketable securities.

The Company classifies its marketable debt securities based on their contractual maturity dates. As of September 30, 2016, the Company’s marketable debt securities mature at various dates through June 2017. The fair values and amortized cost of marketable debt securities by contractual maturity were as follows. The table does not include money market funds that are classified as available-for-sale marketable securities.


	As of September 30, 2016				As of December 31, 2015
Contractual maturity	Fair Value		Amortized Cost		Fair Value		Amortized Cost
Less than one year	$	47,117	$	47,116	$	49,653	$	49,657

During the nine months ended September 30, 2016, the Company sold shares of money market mutual funds with a total fair value of $23,368 that were classified as available-for-sale marketable securities. The cost of the shares of money market mutual funds that were sold was determined by specific identification. Realized gains from those sales amounted to $12.

The following tables show the fair value of the Company’s available-for-sale marketable securities that have unrealized losses and that are deemed to be only temporarily impaired, aggregated by investment category and length of time that the individual investments have been in a continuous unrealized loss position.


	Less than 12 Months					12 Months or Greater				Total
As of September 30, 2016	Fair Value		Gross Unrealized Losses			Fair Value		Gross Unrealized Losses		Fair Value		Gross Unrealized Losses
Corporate bonds	$	9,528	$	(5	)	$	—	$	—	$	9,528	$	(5	)
Commercial paper		9,443		(3	)		—		—		9,443		(3	)

Total	$	18,970	$	(8	)	$	—	$	—	$	18,970	$	(8	)


	Less than 12 Months					12 Months or Greater				Total
As of December 31, 2015	Fair Value		Gross Unrealized Losses			Fair Value		Gross Unrealized Losses		Fair Value		Gross Unrealized Losses
Money market mutual funds	$	30,985	$	(31	)	$	—	$	—	$	30,985	$	(31	)
Corporate bonds		14,187		(6	)		—		—		14,187		(6	)
Commercial paper		11,960		(3	)		—		—		11,960		(3	)

Total	$	57,132	$	(40	)	$	—	$	—	$	57,132	$	(40	)

As of September 30, 2016 and December 31, 2015, the Company held a total of 20 out of 41 positions and 15 out of 23 positions, respectively, that were in an unrealized loss position, none of which had been in an unrealized loss position for 12 months or greater. Based on the Company’s review of these securities, the Company believes that the cost basis of its available-for-sale marketable securities is recoverable and that, therefore, it had no other-than-temporary impairments on these securities as of September 30, 2016 and December 31, 2015. The Company does not intend to sell these debt securities and the Company believes it is not more likely than not that it will be required to sell these securities before the recovery of their amortized cost basis, which may be maturity.

- Definition

The entire disclosure for investments in certain debt and equity securities.

+ References + Details

Accumulated Other Comprehensive Income (Loss)

9 Months Ended

Sep. 30, 2016

Equity [Abstract]

Accumulated Other Comprehensive Income (Loss)

4.	Accumulated Other Comprehensive Income (Loss)

The following table summarizes the changes in accumulated other comprehensive income (loss), or AOCI, net of tax, from unrealized gains (losses) on available-for-sale marketable securities, the Company’s only component of AOCI, for the nine months ended September 30, 2016. For the nine months ended September 30, 2015, all of the Company’s funds were held in money market savings and checking accounts that were classified as cash equivalents and not as available-for-sale marketable securities.


	Total Accumulated Other Comprehensive Income (Loss)
Balance, December 31, 2015	$	(35	)

Other comprehensive income before reclassifications		67
Amount reclassified out of accumulated other comprehensive income		(12	)

Net current period other comprehensive income		55

Balance, September 30, 2016	$	20

The reclassifications out of AOCI and into net loss were as follows:


	Amounts Reclassified out of AOCI
Component of AOCI	Three Months Ended September 30,		Nine Months Ended September 30,		Affected Line Item in the Condensed Statements of Comprehensive Loss
Component of AOCI	2016		2016
Unrealized gains (losses) on available-for-sale marketable securities
Realized gains on sale of securities	$	12	$	12		Other income
		—		—		Income tax benefit

	$	12	$	12		Net of tax

The amount reclassified out of AOCI into net loss was determined by specific identification.

- Definition

The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e689-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=66004124&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e640-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e716-108580

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e709-108580

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e637-108580

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=66004124&loc=d3e681-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Reclassification Adjustments
-URI http://asc.fasb.org/extlink&oid=6522872

+ Details

Fair Value Measurements

9 Months Ended

Sep. 30, 2016

Fair Value Disclosures [Abstract]

Fair Value Measurements

5.	Fair Value Measurements

As of September 30, 2016 and December 31, 2015, the Company’s financial instruments consist of cash and cash equivalents, available-for-sale marketable securities, restricted cash, accounts payable and accrued liabilities. The fair values of cash and cash equivalents, restricted cash, accounts payable and accrued liabilities approximate their carrying values due to the short-term nature of these financial instruments. Marketable securities are reported on the Company’s Condensed Balance Sheets at their fair values, based upon pricing of securities with the same or similar investment characteristics as provided by third-party pricing services, as described below.

Current accounting guidance defines fair value, establishes a framework for measuring fair value in accordance with ASC section 820, and requires certain disclosures about fair value measurements. The valuation techniques included in the guidance are based on observable and unobservable inputs. Observable inputs reflect readily obtainable data from independent sources, while unobservable inputs reflect the Company’s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances.

The Company classifies its investments in a fair value hierarchy that is intended to increase consistency and comparability in fair value measurements and related disclosures. The fair value hierarchy is divided into three levels based on the source of inputs as follows:

•

Level 1 – Observable inputs – quoted prices in active markets for identical assets and liabilities.

•

Level 2 – Observable inputs other than the quoted prices in active markets for identical assets and liabilities – such as quoted prices for similar instruments, quoted prices for identical or similar instruments in inactive markets, or other inputs that are observable or can be corroborated by observable market data.

•

Level 3 – Unobservable inputs – includes amounts derived from valuation models where one or more significant inputs are unobservable and require the Company to develop relevant assumptions.

Valuation Techniques - Level 2 Inputs

The Company estimates the fair values of its financial instruments categorized as level 2 in the fair value hierarchy, including U.S. Treasury securities, U.S. government agency obligations, corporate bonds, commercial paper and money market funds with similar underlying investments, by taking into consideration valuations obtained from third-party pricing services. The pricing services use industry standard valuation models, including both income- and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, benchmark yields, issuer credit spreads, benchmark securities, and other observable inputs. The Company obtains a single price for each financial instrument and does not adjust the prices obtained from the pricing service.

The Company validates the prices provided by its third-party pricing services by reviewing their pricing methods, obtaining market values from other pricing sources and comparing them to the share prices presented by the third-party pricing services. After completing its validation procedures, the Company did not adjust or override any fair value measurements provided by its third-party pricing services as of September 30, 2016 or December 31, 2015.

The following tables summarize the Company’s financial assets measured at fair value on a recurring basis as of September 30, 2016 and December 31, 2015.

Fair value measurement as of September 30, 2016


Financial assets	Total		Quoted prices in active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Type of Instrument

Cash and cash equivalents:
Money market mutual funds, savings account and checking accounts	$	5,426	$	5,426	$	—	$	—

Available-for-sale marketable securities:
Money market mutual funds		18,877		—		18,877		—
U.S. Treasury securities		2,502		—		2,502		—
U.S. government agency obligations		8,890		—		8,890		—
Corporate bonds		15,051		—		15,051		—
Commercial paper		20,674		—		20,674		—
Restricted cash:
Commercial money market account		1,469		1,469		—		—

Total financial assets	$	72,889	$	6,895	$	65,994	$	—

Fair value measurement as of December 31, 2015:


Financial assets	Total		Quoted prices in active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Type of Instrument

Cash and cash equivalents:
Money market mutual funds, savings account and checking accounts	$	15,101	$	15,101	$	—	$	—

Available-for-sale marketable securities:
Money market mutual funds		41,986				41,986		—
U.S. Treasury securities		2,528				2,528		—
U.S. government agency obligations		13,496				13,496		—
Corporate bonds		14,188				14,188		—
Commercial paper		19,442				19,442		—
Restricted cash:
Bank Certificate of Deposit		700		700		—		—

Total financial assets	$	107,441	$	15,801	$	91,640	$	—

There were no purchases, sales or maturities of Level 3 financial assets and no unrealized gains or losses related to Level 3 available-for-sale marketable securities for the nine months ended September 30, 2016. There were no transfers of financial assets between Levels 1, 2, or 3 classifications during the nine months ended September 30, 2016.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Restricted Cash

9 Months Ended

Sep. 30, 2016

Receivables [Abstract]

Restricted Cash

6.	Restricted Cash

The Company is required to maintain stand-by letters of credit as security deposits under each of its leases, one for its operating facility in Shelton, Connecticut and the other for its office space in Stamford, Connecticut (refer to Note 14, Commitments and Contingencies). The fair value of each letter of credit approximates its contract value. In each case, the Company’s bank requires the Company to maintain restricted cash balances to serve as collateral for the letter of credit issued to the respective landlords by the bank. As of September 30, 2016, the restricted cash balances for the Shelton lease and the Stamford lease were both invested in a commercial money market account.

The restricted cash balance for the Shelton lease remains at $700 through the end of the lease term in October 2017. For the Stamford lease, the letter of credit balance remains at $769 for the first three years following commencement of the Stamford lease and may, upon request from the Company, thereafter be reduced to $408 through the end of the lease term in 2023. The reduction in the balance of the letter of credit for the Stamford lease is contingent upon the Company not being in default of any provisions of that lease prior to request for the reduction. As of September 30, 2016 and December 31, 2015, the Company had $1,469 and $700 of restricted cash, respectively, in long-term assets.

Prepaid Expenses

9 Months Ended

Sep. 30, 2016

Text Block [Abstract]

Prepaid Expenses

7.	Prepaid expenses

As of September 30, 2016, prepaid expenses were $4,820, consisting of $4,363 of prepaid R&D clinical costs, $327 of prepaid insurance and $130 of other prepaid costs. As of December 31, 2015, prepaid expenses were $1,729 consisting of $1,500 of prepaid R&D clinical costs, $98 of prepaid insurance, $96 of prepaid rent, and $35 of other prepaid costs.

Accounts Payable and Accrued Expenses

9 Months Ended

Sep. 30, 2016

Payables and Accruals [Abstract]

Accounts Payable and Accrued Expenses

8.	Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses consist of the following:


	September 30, 2016		December 31, 2015
Accounts payable	$	2,387	$	1,965
Accrued research projects		1,817		1,542
Accrued Shelton lease liability		998		—
Accrued professional fees		373		371
Accrued compensation and benefits		1,177		1,204
Accrued other		73		186

Total	$	6,825	$	5,268

Stockholders' Equity

9 Months Ended

Sep. 30, 2016

Equity [Abstract]

Stockholders' Equity

9.	Stockholders’ Equity

On July 29, 2015, the Company entered into an underwriting agreement with Stifel, Nicolaus & Company, Incorporated and Piper Jaffray & Co., as representatives of the several underwriters named therein, relating to the issuance and sale by the Company of 3,763,440 shares of its common stock (the “Offering”). The Offering was made pursuant to the Company’s Registration Statement on Form S-3 (File No. 333-203072), filed with the SEC on March 27, 2015 and declared effective on May 13, 2015, and a related prospectus supplement dated July 29, 2015, which was filed with the SEC on July 30, 2015. As part of the Offering, the Company granted the underwriters an option to purchase 564,516 additional shares of common stock.

On August 4, 2015, the Company closed the Offering, including the full exercise of the underwriters’ option to purchase 564,516 additional shares of common stock, at a public offering price of $18.60 per share. The Company received net proceeds of approximately $75,231, after deducting the underwriting discounts and commissions and offering expenses paid or payable by the Company.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

Collaborations

9 Months Ended

Sep. 30, 2016

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Collaborations

10.

Collaborations

Chong Kun Dang Pharmaceutical Corporation

In April, 2012, the Company entered into a license agreement with CKD (the “CKD Agreement”) that provides CKD with the exclusive rights to develop, manufacture and commercialize products containing CR845 in South Korea. Under the CKD Agreement, the Company is eligible to receive milestone payments totaling $3,750, relating to pre-defined clinical development ($2,250) and regulatory events ($1,500), as well as royalties on sales of any marketed products containing CR845.

During the three months ended September 30, 2015, the Company met the milestone criteria, as set forth in the CKD Agreement, for the completion of both a Phase 1b trial of Oral CR845 in the United States and a Phase 2 trial of CR845 in uremic pruritus patients in the United States. Both milestones were considered to be substantive and, therefore, the full amount of each of the milestone payments earned, $626 (net of South Korean withholding tax of $124), was recognized as milestone revenue upon achievement of each milestone, of which $417 (net of South Korean withholding tax of $83) was due to the Company as of September 30, 2015.

Maruishi Pharmaceutical Co., Ltd.

In April 2013, the Company entered into a license agreement with Maruishi (the “Maruishi Agreement”) under which the Company granted Maruishi an exclusive license to develop, manufacture, and commercialize drug products containing CR845 for acute pain and uremic pruritus in Japan. Under the Maruishi Agreement, the Company and Maruishi are required to use commercially reasonable efforts, at their own expense, to develop, obtain regulatory approval for and commercialize CR845 in the United States and Japan, respectively. In addition, the Company provided Maruishi specific clinical development services for CR845 used in Maruishi’s field of use.

At inception of the Maruishi Agreement, the Company identified two deliverables under ASC 605-25, Revenue Recognition — Multiple Element Arrangements: (1) the license; and (2) the R&D services specific to the uremic pruritus field of use, both of which were determined to have standalone value and have been accounted for as separate units of accounting from the outset of the arrangement. Upon entering into the Maruishi Agreement, the Company received an upfront, non-refundable, non-creditable license fee of $15,000, a portion of which was assigned to each of the two identified deliverables based on their estimated selling prices. The amount assigned to the R&D services unit of accounting was initially recorded as deferred revenue, which was recognized as collaborative revenue as the services were provided through July 2015. Amortization of deferred revenue pursuant to the R&D services deliverable to collaborative revenue was $89 for the three months ended September 30, 2015 and $1,452 for the nine months ended September 30, 2015.

Under the terms of the Maruishi Agreement, the Company is also entitled to receive aggregate milestone payments of $8,000 for events performed by Maruishi in Japan and $2,500 for events performed by the Company in the United States. In September 2015, Maruishi initiated a Phase 2 clinical trial of CR845 in Japan for uremic pruritus, which triggered a $1,725 milestone payment (net of contractual foreign currency exchange adjustments of $275) to the Company. As of September 30, 2015, such payment was due to the Company. At the time of achievement of the milestone, the Company had delivered all deliverables under the Maruishi Agreement. Since the milestone was achieved in Japan, it was deemed not to be substantive. Accordingly, the Company recognized $1,084 as milestone revenue and $641 as collaborative revenue during both the three months and nine months ended September 30, 2015 in connection with achievement of this milestone.

The Company incurred R&D expense related to the Maruishi Agreement of $108 and $1,583 (both consisting of clinical trial costs related to the R&D services deliverable) during the three and nine months ended September 30, 2015, respectively.

Net Loss Per Share

9 Months Ended

Sep. 30, 2016

Earnings Per Share [Abstract]

Net Loss Per Share

11.

Net Loss Per Share

The Company computes basic net income (loss) per share by dividing net income (loss) by the weighted average number of shares of common stock outstanding. Diluted net income per share includes the potential dilutive effect of common stock equivalents as if such securities were exercised during the period, when the effect is dilutive. Common stock equivalents may include outstanding stock options, which are included using the treasury stock method when dilutive. For the three and nine months ended September 30, 2016 and 2015, the Company excluded the effects of potentially dilutive shares that were outstanding during those respective periods from the denominator as their inclusion would be anti-dilutive due to the Company’s net losses during those periods.

The denominators used in the net loss per share computations are as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2016		2015		2016		2015
Basic:
Weighted average common shares outstanding		27,282,863		25,545,164		27,275,133		23,737,443

Diluted:
Weighted average common shares outstanding - Basic		27,282,863		25,545,164		27,275,133		23,737,443
Common stock options*		—		—		—		—

Denominator for diluted net loss per share		27,282,863		25,545,164		27,275,133		23,737,443

*	No amounts were considered as their effects would be anti-dilutive.

Basic and diluted net loss per share are computed as follows:


	Three Months Ended September 30,						Nine Months Ended September 30,
	2016			2015			2016			2015
Net loss	$	(11,542	)	$	(4,787	)	$	(35,308	)	$	(15,160	)

Weighted-average common shares outstanding:
Basic and Diluted		27,282,863			25,545,164			27,275,133			23,737,443

Net loss per share, Basic and Diluted	$	(0.42	)	$	(0.19	)	$	(1.29	)	$	(0.64	)

As of September 30, 2016 and 2015, 2,299,117 and 1,541,772 stock options, respectively, were outstanding, which could potentially dilute basic earnings per share in the future, but were not included in the computation of diluted net loss per share because to do so would have been anti-dilutive.

Stock-Based Compensation

9 Months Ended

Sep. 30, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock-Based Compensation

12.

Stock-Based Compensation

2014 Equity Incentive Plan

The Company’s 2014 Equity Incentive Plan, or the 2014 Plan, is administered by the Company’s Board of Directors or a duly authorized committee thereof, referred to as the Plan administrator. The 2014 Plan provides for the grant of incentive stock options, non-statutory stock options, restricted stock awards, restricted stock unit awards, stock appreciation rights, performance stock awards and other forms of equity compensation, collectively referred to as Stock Awards. Additionally, the 2014 Plan provides for the grant of performance cash awards. Incentive stock options may be granted only to employees. All other awards may be granted to employees, including officers, non-employee directors, and consultants. No incentive stock options may be granted under the 2014 Plan after the tenth anniversary of the effective date of the 2014 Plan. Stock Awards granted under the 2014 Plan vest at the rate specified by the Plan administrator, which, for employees and non-employee consultants, has generally been 25% on the first anniversary of the date of grant and the balance ratably over the next 36 months. As of January 1, 2016, subsequent grants of Stock Awards made to employees and non-employee consultants vest monthly over a period of four years from the grant date. Stock options initially granted to members of the Company’s Board of Directors vest on the date of the Annual Meeting of Stockholders at which their initial term expires based on the class of Director. Subsequent grants to Directors that are made automatically at Annual Meetings of Stockholders vest fully on the first anniversary of the date of grant. The Plan administrator determines the term of Stock Awards granted under the 2014 Plan up to a maximum of ten years.

The aggregate number of shares of the Company’s common stock reserved for issuance under the 2014 Plan will automatically increase on January 1 of each year, beginning on January 1, 2015 and continuing through and including January 1, 2024, by 3% of the total number of shares of the Company’s capital stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares determined by the Company’s Board of Directors. On January 1, 2016, the aggregate number of shares of common stock that may be issued pursuant to stock awards under the 2014 Plan automatically increased from 2,284,061 to 3,101,707. The maximum number of shares that may be issued pursuant to the exercise of incentive stock options under the 2014 Plan is 30,000,000 shares.

Under the 2014 Plan, the Company granted 75,000 and 797,000 stock options during the three and nine months ended September 30, 2016, respectively, and 25,000 and 629,000 stock options during the three and nine months ended September 30, 2015, respectively. The fair values of stock options granted during the three and nine months ended September 30, 2016 and 2015 were estimated as of the dates of grant using the Black-Scholes option pricing model with the following assumptions:


	Three Months Ended September 30,		Nine Months Ended September 30,
	2016	2015	2016	2015
Risk-free interest rate	1.19%	1.77%	1.19% - 1.79%	1.43% - 1.89%
Expected volatility	71.9%	64.1%	67.8% - 72.6%	64.0% - 67.1%
Expected dividend yield	0%	0%	0%	0%
Expected life of employee options (in years)	6.25	6.25	6.25	6.25
Expected life of nonemployee options (in years)	—	—	10	10

The weighted average grant date fair value of options granted to employees and members of the Company’s Board of Directors for their service during the three and nine months ended September 30, 2016 was $3.92 and $3.81, respectively, and during the three and nine months ended September 30, 2015 was $13.30 and $6.60, respectively.

The weighted average fair value of outstanding options that had been granted to nonemployee consultants, as re-measured during the vesting period of each tranche in accordance with ASC 505-50, was $5.75 and $4.16 during the three and nine months ended September 30, 2016, respectively, and $10.87 and $9.03 during the three and nine months ended September 30, 2015, respectively.

During the three and nine months ended September 30, 2016 and 2015, the Company recognized compensation expense relating to stock options, as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2016		2015		2016		2015
Research and development	$	375	$	283	$	867	$	761
General and administrative		402		378		1,104		1,046

Total stock option expense	$	777	$	661	$	1,971	$	1,807

A summary of stock option award activity related to employees, non-employee members of the Company’s Board of Directors and non-employee consultants as of and for the nine months ended September 30, 2016 is presented below:


	Number of Shares			Weighted Average Exercise Price
Outstanding, December 31, 2015		1,658,408		$	10.27
Granted		797,000			5.99
Exercised		(28,000	)		1.41
Forfeited		(95,792	)		12.15
Expired		(32,499	)		11.03

Outstanding, September 30, 2016		2,299,117			8.80

Options exercisable, September 30, 2016		887,213		$	8.98

The Company does not expect to realize any tax benefits from its stock option activity or the recognition of stock-based compensation expense because the Company currently has net operating losses and has a full valuation allowance against its deferred tax assets. Accordingly, no amounts related to excess tax benefits have been reported in cash flows from operations or cash flows from financing activities for the nine months ended September 30, 2016 and 2015.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

Income Taxes

9 Months Ended

Sep. 30, 2016

Income Tax Disclosure [Abstract]

Income Taxes

13.

Income Taxes

For the three months ended September 30, 2016 and 2015, pre-tax losses were $11,597 and $4,987, respectively, and for the nine months ended September 30, 2016 and 2015, pre-tax losses were $35,587 and $15,410, respectively. The Company recognized a full tax valuation allowance against its deferred tax assets as of September 30, 2016 and December 31, 2015.

The benefit from income taxes of $55 and $200 for the three months ended September 30, 2016 and 2015, respectively, and $279 and $250 for the nine months ended September 30, 2016 and 2015, respectively, relates to state R&D tax credits exchanged for cash pursuant to the Connecticut R&D Tax Credit Exchange Program, which permits qualified small businesses engaged in R&D activities within Connecticut to exchange their unused R&D tax credits for a cash amount equal to 65% of the value of the exchanged credits.

Commitments and Contingencies

9 Months Ended

Sep. 30, 2016

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

14.

Commitments and Contingencies

Contractual obligations and commitments as of September 30, 2016 were as follows:


	Payment Due for the Year Ending December 31,
	2016		2017		2018		2019		2020		Thereafter		Total
Stamford operating lease	$	192	$	875	$	1,093	$	1,217	$	1,241	$	3,650	$	8,268
Shelton operating lease		232		740		—		—		—		—		972

	$	425	$	1,615	$	1,093	$	1,217	$	1,241	$	3,650	$	9,241

In May 2016, the Company moved its headquarters to Stamford, Connecticut, where it leases office space under an operating lease with a term through October 2023 (See Note 21 of Notes to Financial Statements, Commitments and Contingencies, in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015). As of September 30, 2016, the Stamford landlord had made tenant improvements of approximately $1,094 to the leased premises. Such amount is included in Property and equipment, net and in Deferred lease obligation on the Company’s Condensed Balance Sheet. The portion of Deferred lease obligation that is related to tenant improvements is being amortized as a reduction to rent expense over the same term as rent expense. During the three and nine months ended September 30, 2016, the Company amortized $36 and $71, respectively, of Deferred lease obligation related to tenant improvements.

As of September 30, 2016, the Company continues to lease its former operating facility located in Shelton, Connecticut, which has a term through October 2017 (See Note 21 of Notes to Financial Statements, Commitments and Contingencies, in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015). The Company accelerated the amortization of the Shelton leasehold improvements through May 2016, the date the Company moved from the Shelton facility, or cease-use date, at which time the net book value of those leasehold improvements was zero. Acceleration of amortization of the Shelton leasehold improvements resulted in $899 of additional amortization expense (additional net loss per share of $0.03) for the nine months ended September 30, 2016.

In addition, in accordance with the accounting guidance in ASC 420-10-25-13 regarding exit or disposal cost obligations, as of May 2016, the Company recorded rent expense, within Research and development expense and General and administrative expense, and accrued a liability of $1,312, which represents the fair value of costs that will continue to be incurred during the remaining term of the Shelton operating lease without economic benefit to the Company. As of September 30, 2016, the carrying amount of the liability of $998, which includes the $972 of minimum rental payments in the table above, together with common area maintenance charges, was included in Accounts payable and accrued expenses on the Company’s Condensed Balance Sheet. At the cease-use date, the Company also wrote off the balance of Deferred lease obligation of $429 related to the Shelton lease.

A reconciliation of the balances of the accrued Shelton lease cease-use liability for the nine months ended September 30, 2016 is as follows:


Balance, January 1, 2016	$	—
Additional accruals		1,312
Rental payments		(314	)

Balance, September 30, 2016	$	998

Basis of Presentation (Policies)	9 Months Ended
Basis of Presentation (Policies)	Sep. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities, as of the date of the financial statements as well as the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from the Company’s estimates and assumptions. Significant estimates include the fair value of marketable securities that are classified as level 2 of the fair value hierarchy, useful lives of fixed assets, the periods over which certain revenues will be recognized, including licensing and collaborative revenue recognized from non-refundable up-front and milestone payments, the determination of prepaid research and development, or R&D, clinical costs and accrued research projects, the amount of non-cash compensation costs related to share-based payments to employees and non-employees and the periods over which those costs are expensed and the likelihood of realization of deferred tax assets.
Significant Accounting Policies	The unaudited interim condensed financial statements included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission, or the SEC. Accordingly, they do not include all information and disclosures necessary for a presentation of the Company’s financial position, results of operations and cash flows in conformity with generally accepted accounting principles in the United States of America, or GAAP. In the opinion of management, these unaudited interim financial statements reflect all adjustments, consisting primarily of normal recurring accruals, necessary for a fair presentation of results for the periods presented. The results of operations for interim periods are not necessarily indicative of the results for the full year. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from this report, as is permitted by SEC rules and regulations; however, the Company believes that the disclosures are adequate to make the information presented not misleading. The condensed balance sheet data for the year ended December 31, 2015 were derived from audited financial statements, but do not include all disclosures required by GAAP. These unaudited interim condensed financial statements should be read in conjunction with the audited financial statements and accompanying notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015. Significant Accounting Policies There have been no material changes to the significant accounting policies previously disclosed in Note 2 to the Financial Statements in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In June 2016, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, No. 2016-13, Financial Instruments—Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments, or ASU 2016-13, which replaces the incurred loss impairment methodology in current GAAP, that delays recognition of a credit loss until it is probable that such loss has been incurred, with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. ASU 2016-13 modifies the other-than-temporary impairment model for available-for-sale debt securities by requiring (1) estimating expected credit losses only when the fair value is below the amortized cost of the asset; (2) recording a credit loss without regard to the length of time a security has been in an unrealized loss position; (3) limiting the measurement of the credit loss to the difference between the security’s amortized cost basis and its fair value and (4) presenting credit losses as an allowance rather than as a write-down, which will allow the Company to record reversals of credit losses in current period net income, a practice that is currently prohibited. ASU 2016-13 will be effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. The Company is currently evaluating the effect that adoption of ASU 2016-13 will have on its results of operations, financial position and cash flows. In May 2016, the FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients, or ASU 2016-12, which amends guidance in the new revenue standard, ASU No. 2014-09 Revenue from Contracts with Customers (Topic 606), or ASU 2014-09, on collectability, noncash consideration, presentation of sales tax and transition. The amendments in ASU 2016-12 are effective for annual reporting periods beginning after December 15, 2017 (i.e., January 1, 2018), including interim periods within those reporting periods, which is the same as for ASU 2014-09, as amended by ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, or ASU 2015-14. The Company is currently evaluating the effect that adoption of ASU 2016-12 will have on its financial statements. In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606), Identifying Performance Obligations and Licensing, or ASU 2016-10, which clarifies the principle for determining whether a good or service is “separately identifiable” from other promises in the contract and, therefore, should be accounted for as a separate performance obligation. In that regard, ASU 2016-10 requires that an entity determine whether its promise is to transfer individual goods or services to the customer, or a combined item (or items) to which the individual goods and services are inputs. In addition, ASU 2016-10 categorizes intellectual property, or IP, into two categories: “functional” and “symbolic.” Functional IP has significant standalone functionality. All other IP is considered symbolic IP. Revenue from licenses of functional IP is generally recognized at a point in time, while revenue from licenses of symbolic IP is recognized over time. ASU 2016-10 has the same effective date and transition requirements as ASU 2014-09, as amended by ASU 2015-14. The Company is currently evaluating the effect that adoption of ASU 2016-10 will have on its financial statements. In March 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers (Topic 606), Principal versus Agent Considerations (Reporting Revenue Gross versus Net), or ASU 2016-08, which clarifies the implementation guidance on principal versus agent considerations contained in ASU 2014-09 by specifying that the determination as to whether an entity that is involved in providing a good or a service to a customer is a principal or an agent is based upon whether the entity controls the good or the service before it is transferred to the customer. ASU 2016-08 has the same effective date and transition requirements as ASU 2014-09, as amended by ASU 2015-14. The Company is currently evaluating the effect that adoption of ASU 2016-08 will have on its financial statements. In March 2016, the FASB issued ASU No. 2016-09, Improvements to Employee Share-Based Payment Accounting, or ASU 2016-09, which amends Accounting Standards Codification, or ASC, Topic 718, Compensation – Stock Compensation. ASU 2016-09 simplifies several aspects of the accounting for share-based payment transactions, including the accounting for forfeitures, income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years and early adoption is permitted. Certain of the amendments will be applied using a modified retrospective transition method by means of a cumulative-effect adjustment to equity as of the beginning of the period in which ASU 2016-09 is adopted, while other amendments will be applied retrospectively, prospectively or using either a prospective or a retrospective transition method. Upon adoption on January 1, 2017, the Company will account for forfeitures as they occur rather than estimate a forfeiture rate and will record a cumulative-effect adjustment in equity on the date of initial adoption. In periods subsequent to adoption, a higher expense will be recognized related to stock-based awards that are not forfeited. The Company expects that the income tax amendments within ASU 2016-09 will have no impact on its results of operations or cash flows because it is in a net operating loss position with a full valuation allowance. In May 2014, the FASB issued ASU 2014-09, which changes the principle under which the Company will recognize revenue from contracts with customers from one which requires the Company to satisfy specific criteria before recognizing revenue to one which requires the Company to recognize revenue in an amount that reflects the consideration to which it expects to be entitled in exchange for the transfer of promised goods or services to customers. ASU 2014-09, as amended by ASU 2015-14, is effective for annual reporting periods beginning after December 15, 2017 (i.e., January 1, 2018), including interim periods within those reporting periods. The standard allows for two transition methods: (1) retrospectively to each prior reporting period presented, or (2) using a modified retrospective approach, with the cumulative effect of initially applying ASU 2014-09 recognized as an adjustment to the opening balance of retained earnings at the date of initial adoption. The Company is currently in the process of deciding which method of transition it will use and the effect of adoption of ASU 2014-09 on its results of operations, financial position and cash flows. The Company currently recognizes revenue only from contracts with Maruishi and CKD, under both of which the Company may earn future milestone payments upon the achievement of defined clinical and regulatory events. The Company is continuing to monitor the timing of achievement of such milestones. To the extent that all defined milestones have not been achieved and the related revenue recognized under current GAAP prior to the adoption of ASU 2014-09, those contracts will be included within the scope of ASU 2014-09. However, since the current accounting for those contracts, as multiple element arrangements with milestone revenue recognized using the milestone method, is similar to ASU 2014-09, the Company does not expect a material effect on its financial statements from the adoption of ASU 2014-09.

Available-for-Sale Marketable Securities (Tables)

9 Months Ended

Sep. 30, 2016

Investments, Debt and Equity Securities [Abstract]

Summary of Available-for-Sale Marketable Securities by Major Type of Security

The following tables summarize the Company’s available-for-sale marketable securities by major type of security as of September 30, 2016 and December 31, 2015:

As of September 30, 2016


			Gross Unrealized
Type of Security	Amortized Cost		Gains		Losses			Estimated Fair Value
Money market mutual funds	$	18,858	$	19	$	—		$	18,877
U.S. Treasury securities		2,501		1		—			2,502
U.S. government agency obligations		8,886		4		—			8,890
Corporate bonds		15,054		2		(5	)		15,051
Commercial paper		20,675		2		(3	)		20,674

Total available-for-sale marketable securities	$	65,974	$	28	$	(8	)	$	65,994

As of December 31, 2015


			Gross Unrealized
Type of Security	Amortized Cost		Gains		Losses			Estimated Fair Value
Money market mutual funds	$	42,017	$	—	$	(31	)	$	41,986
U.S. Treasury securities		2,528		—		—			2,528
U.S. government agency obligations		13,492		4		—			13,496
Corporate bonds		14,194		—		(6	)		14,188
Commercial paper		19,444		1		(3	)		19,442

Total available-for-sale marketable securities	$	91,675	$	5	$	(40	)	$	91,640

Schedule of Fair Values and Amortized Cost of Marketable Debt Securities by Contractual Maturity


	As of September 30, 2016				As of December 31, 2015
Contractual maturity	Fair Value		Amortized Cost		Fair Value		Amortized Cost
Less than one year	$	47,117	$	47,116	$	49,653	$	49,657

Schedule of Fair Values and Continuous Unrealized Loss Positions of Available-for-Sale Marketable Securities


	Less than 12 Months					12 Months or Greater				Total
As of September 30, 2016	Fair Value		Gross Unrealized Losses			Fair Value		Gross Unrealized Losses		Fair Value		Gross Unrealized Losses
Corporate bonds	$	9,528	$	(5	)	$	—	$	—	$	9,528	$	(5	)
Commercial paper		9,443		(3	)		—		—		9,443		(3	)

Total	$	18,970	$	(8	)	$	—	$	—	$	18,970	$	(8	)


	Less than 12 Months					12 Months or Greater				Total
As of December 31, 2015	Fair Value		Gross Unrealized Losses			Fair Value		Gross Unrealized Losses		Fair Value		Gross Unrealized Losses
Money market mutual funds	$	30,985	$	(31	)	$	—	$	—	$	30,985	$	(31	)
Corporate bonds		14,187		(6	)		—		—		14,187		(6	)
Commercial paper		11,960		(3	)		—		—		11,960		(3	)

Total	$	57,132	$	(40	)	$	—	$	—	$	57,132	$	(40	)

- Definition

Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.

+ References + Details

Accumulated Other Comprehensive Income (Loss) (Tables)

9 Months Ended

Sep. 30, 2016

Equity [Abstract]

Summary of Changes in Accumulated Other Comprehensive Income (Loss), Net of Tax, from Unrealized Gains (Losses) on Available-for-Sale Marketable Securities


	Total Accumulated Other Comprehensive Income (Loss)
Balance, December 31, 2015	$	(35	)

Other comprehensive income before reclassifications		67
Amount reclassified out of accumulated other comprehensive income		(12	)

Net current period other comprehensive income		55

Balance, September 30, 2016	$	20

Schedule of Reclassification Out of Accumulated Other Comprehensive Income

The reclassifications out of AOCI and into net loss were as follows:


	Amounts Reclassified out of AOCI
Component of AOCI	Three Months Ended September 30,		Nine Months Ended September 30,		Affected Line Item in the Condensed Statements of Comprehensive Loss
Component of AOCI	2016		2016
Unrealized gains (losses) on available-for-sale marketable securities
Realized gains on sale of securities	$	12	$	12		Other income
		—		—		Income tax benefit

	$	12	$	12		Net of tax

Fair Value Measurements (Tables)

9 Months Ended

Sep. 30, 2016

Fair Value Disclosures [Abstract]

Summary of Financial Assets Measured at Fair Value on Recurring Basis

The following tables summarize the Company’s financial assets measured at fair value on a recurring basis as of September 30, 2016 and December 31, 2015.

Fair value measurement as of September 30, 2016


Financial assets	Total		Quoted prices in active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Type of Instrument

Cash and cash equivalents:
Money market mutual funds, savings account and checking accounts	$	5,426	$	5,426	$	—	$	—

Available-for-sale marketable securities:
Money market mutual funds		18,877		—		18,877		—
U.S. Treasury securities		2,502		—		2,502		—
U.S. government agency obligations		8,890		—		8,890		—
Corporate bonds		15,051		—		15,051		—
Commercial paper		20,674		—		20,674		—
Restricted cash:
Commercial money market account		1,469		1,469		—		—

Total financial assets	$	72,889	$	6,895	$	65,994	$	—

Fair value measurement as of December 31, 2015:


Financial assets	Total		Quoted prices in active markets for identical assets (Level 1)		Significant other observable inputs (Level 2)		Significant unobservable inputs (Level 3)
Type of Instrument

Cash and cash equivalents:
Money market mutual funds, savings account and checking accounts	$	15,101	$	15,101	$	—	$	—

Available-for-sale marketable securities:
Money market mutual funds		41,986				41,986		—
U.S. Treasury securities		2,528				2,528		—
U.S. government agency obligations		13,496				13,496		—
Corporate bonds		14,188				14,188		—
Commercial paper		19,442				19,442		—
Restricted cash:
Bank Certificate of Deposit		700		700		—		—

Total financial assets	$	107,441	$	15,801	$	91,640	$	—

Accounts Payable and Accrued Expenses (Tables)

9 Months Ended

Sep. 30, 2016

Payables and Accruals [Abstract]

Schedule of Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses consist of the following:


	September 30, 2016		December 31, 2015
Accounts payable	$	2,387	$	1,965
Accrued research projects		1,817		1,542
Accrued Shelton lease liability		998		—
Accrued professional fees		373		371
Accrued compensation and benefits		1,177		1,204
Accrued other		73		186

Total	$	6,825	$	5,268

Net Loss Per Share (Tables)

9 Months Ended

Sep. 30, 2016

Earnings Per Share [Abstract]

Computation of Denominators Used in Net Loss per Share

The denominators used in the net loss per share computations are as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2016		2015		2016		2015
Basic:
Weighted average common shares outstanding		27,282,863		25,545,164		27,275,133		23,737,443

Diluted:
Weighted average common shares outstanding - Basic		27,282,863		25,545,164		27,275,133		23,737,443
Common stock options*		—		—		—		—

Denominator for diluted net loss per share		27,282,863		25,545,164		27,275,133		23,737,443

*	No amounts were considered as their effects would be anti-dilutive.

Computation of Basic and Diluted Net Loss per Share

Basic and diluted net loss per share are computed as follows:


	Three Months Ended September 30,						Nine Months Ended September 30,
	2016			2015			2016			2015
Net loss	$	(11,542	)	$	(4,787	)	$	(35,308	)	$	(15,160	)

Weighted-average common shares outstanding:
Basic and Diluted		27,282,863			25,545,164			27,275,133			23,737,443

Net loss per share, Basic and Diluted	$	(0.42	)	$	(0.19	)	$	(1.29	)	$	(0.64	)

Stock-Based Compensation (Tables)

9 Months Ended

Sep. 30, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Summary of Assumptions Used in Black-Scholes Option Pricing Model

The fair values of stock options granted during the three and nine months ended September 30, 2016 and 2015 were estimated as of the dates of grant using the Black-Scholes option pricing model with the following assumptions:


	Three Months Ended September 30,		Nine Months Ended September 30,
	2016	2015	2016	2015
Risk-free interest rate	1.19%	1.77%	1.19% - 1.79%	1.43% - 1.89%
Expected volatility	71.9%	64.1%	67.8% - 72.6%	64.0% - 67.1%
Expected dividend yield	0%	0%	0%	0%
Expected life of employee options (in years)	6.25	6.25	6.25	6.25
Expected life of nonemployee options (in years)	—	—	10	10

Summary of Compensation Expense Relating to Stock Options

During the three and nine months ended September 30, 2016 and 2015, the Company recognized compensation expense relating to stock options, as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2016		2015		2016		2015
Research and development	$	375	$	283	$	867	$	761
General and administrative		402		378		1,104		1,046

Total stock option expense	$	777	$	661	$	1,971	$	1,807

Summary of Stock Option Award Activity


	Number of Shares			Weighted Average Exercise Price
Outstanding, December 31, 2015		1,658,408		$	10.27
Granted		797,000			5.99
Exercised		(28,000	)		1.41
Forfeited		(95,792	)		12.15
Expired		(32,499	)		11.03

Outstanding, September 30, 2016		2,299,117			8.80

Options exercisable, September 30, 2016		887,213		$	8.98

Commitments and Contingencies (Tables)

9 Months Ended

Sep. 30, 2016

Commitments and Contingencies Disclosure [Abstract]

Schedule of Contractual Obligations and Commitments

Contractual obligations and commitments as of September 30, 2016 were as follows:


	Payment Due for the Year Ending December 31,
	2016		2017		2018		2019		2020		Thereafter		Total
Stamford operating lease	$	192	$	875	$	1,093	$	1,217	$	1,241	$	3,650	$	8,268
Shelton operating lease		232		740		—		—		—		—		972

	$	425	$	1,615	$	1,093	$	1,217	$	1,241	$	3,650	$	9,241

Schedule of Reconciliation of Balances of Accrued Shelton Lease Cease-Use Liability

A reconciliation of the balances of the accrued Shelton lease cease-use liability for the nine months ended September 30, 2016 is as follows:


Balance, January 1, 2016	$	—
Additional accruals		1,312
Rental payments		(314	)

Balance, September 30, 2016	$	998

Business - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Nature Of Business [Line Items]
Date of formation			Jul. 02, 2004
Proceeds from equity and debt financing	$ 204,800		$ 204,800
Upfront and milestone payments received in connection with license agreements	32,500		32,500
Unrestricted cash and cash equivalents and marketable securities	71,420		71,420
Accumulated deficit	(140,199)		(140,199)		$ (104,891)
Net loss	$ (11,542)	$ (4,787)	(35,308)	$ (15,160)
Net cash used in operating activities			$ (34,193)	$ (17,310)
Minimum [Member]
Nature Of Business [Line Items]
Expected period to fund operations			1 year

Available-for-Sale Marketable Securities - Summary of Available-for-Sale Marketable Securities by Major Type of Security (Detail) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	$ 65,974	$ 91,675
Gross Unrealized Gains	28	5
Gross Unrealized Losses	(8)	(40)
Estimated Fair Value	65,994	91,640
Money Market Mutual Funds [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	18,858	42,017
Gross Unrealized Gains	19
Gross Unrealized Losses		(31)
Estimated Fair Value	18,877	41,986
U.S. Treasury Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	2,501	2,528
Gross Unrealized Gains	1
Estimated Fair Value	2,502	2,528
US Government Corporations and Agencies Securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	8,886	13,492
Gross Unrealized Gains	4	4
Estimated Fair Value	8,890	13,496
Corporate Bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	15,054	14,194
Gross Unrealized Gains	2
Gross Unrealized Losses	(5)	(6)
Estimated Fair Value	15,051	14,188
Commercial Paper [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost	20,675	19,444
Gross Unrealized Gains	2	1
Gross Unrealized Losses	(3)	(3)
Estimated Fair Value	$ 20,674	$ 19,442

Available-for-Sale Marketable Securities - Schedule of Fair Values and Amortized Cost of Marketable Debt Securities by Contractual Maturity (Detail) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Investments, Debt and Equity Securities [Abstract]
Fair value of marketable debt securities, contractual maturity, Less than one year	$ 47,117	$ 49,653
Amortized Cost of marketable debt securities, contractual maturity, Less than one year	$ 47,116	$ 49,657

Available-for-Sale Marketable Securities - Additional Information (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2016 USD ($) Position	Dec. 31, 2015 Position
Schedule of Available-for-sale Securities [Line Items]
Proceeds from sale of available-for-sale marketable securities	$ 23,368
Realized gains or losses	$ 12
Number of available-for-sale marketable securities in unrealized loss positions \| Position	20	15
Total number of positions \| Position	41	23
Money Market Mutual Funds [Member]
Schedule of Available-for-sale Securities [Line Items]
Proceeds from sale of available-for-sale marketable securities	$ 23,368
Realized gains or losses	$ 12

Available-for-Sale Marketable Securities - Schedule of Fair Values and Continuous Unrealized Loss Positions of Available-for-Sale Marketable Securities (Detail) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale marketable securities, continuous unrealized loss position, Less than 12 Months, Fair Value	$ 18,970	$ 57,132
Available-for-sale marketable securities, continuous unrealized loss position, Less than 12 Months, Gross Unrealized Losses	(8)	(40)
Available-for-sale marketable securities, continuous unrealized loss position, 12 Months or Greater, Fair Value	0	0
Available-for-sale marketable securities, continuous unrealized loss position, 12 Months or Greater, Gross Unrealized Losses	0	0
Available-for-sale marketable securities, continuous unrealized loss position, Fair Value	18,970	57,132
Available-for-sale marketable securities, continuous unrealized loss position, Gross Unrealized Losses	(8)	(40)
Money Market Mutual Funds [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale marketable securities, continuous unrealized loss position, Less than 12 Months, Fair Value		30,985
Available-for-sale marketable securities, continuous unrealized loss position, Less than 12 Months, Gross Unrealized Losses		(31)
Available-for-sale marketable securities, continuous unrealized loss position, 12 Months or Greater, Fair Value		0
Available-for-sale marketable securities, continuous unrealized loss position, 12 Months or Greater, Gross Unrealized Losses		0
Available-for-sale marketable securities, continuous unrealized loss position, Fair Value		30,985
Available-for-sale marketable securities, continuous unrealized loss position, Gross Unrealized Losses		(31)
Corporate Bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale marketable securities, continuous unrealized loss position, Less than 12 Months, Fair Value	9,528	14,187
Available-for-sale marketable securities, continuous unrealized loss position, Less than 12 Months, Gross Unrealized Losses	(5)	(6)
Available-for-sale marketable securities, continuous unrealized loss position, 12 Months or Greater, Fair Value	0	0
Available-for-sale marketable securities, continuous unrealized loss position, 12 Months or Greater, Gross Unrealized Losses	0	0
Available-for-sale marketable securities, continuous unrealized loss position, Fair Value	9,528	14,187
Available-for-sale marketable securities, continuous unrealized loss position, Gross Unrealized Losses	(5)	(6)
Commercial Paper [Member]
Schedule of Available-for-sale Securities [Line Items]
Available-for-sale marketable securities, continuous unrealized loss position, Less than 12 Months, Fair Value	9,443	11,960
Available-for-sale marketable securities, continuous unrealized loss position, Less than 12 Months, Gross Unrealized Losses	(3)	(3)
Available-for-sale marketable securities, continuous unrealized loss position, 12 Months or Greater, Fair Value	0	0
Available-for-sale marketable securities, continuous unrealized loss position, 12 Months or Greater, Gross Unrealized Losses	0	0
Available-for-sale marketable securities, continuous unrealized loss position, Fair Value	9,443	11,960
Available-for-sale marketable securities, continuous unrealized loss position, Gross Unrealized Losses	$ (3)	$ (3)

Accumulated Other Comprehensive Income (Loss) - Summary of Changes in Accumulated Other Comprehensive Income (Loss), Net of Tax, from Unrealized Gains (Losses) on Available-for-Sale Marketable Securities (Detail) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2016
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Total Accumulated Other Comprehensive Income (Loss), Beginning Balance		$ (35)
Other comprehensive income before reclassifications		67
Amount reclassified out of accumulated other comprehensive income	$ (12)	(12)
Net current period other comprehensive income		55
Total Accumulated Other Comprehensive Income (Loss), Ending Balance	$ 20	$ 20

Accumulated Other Comprehensive Income (Loss) - Schedule of Reclassifications Out of Accumulated Other Comprehensive Income (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Realized gains on sale of securities,Other income	$ 176	$ 22	$ 498	$ 49
Income tax benefit	(55)	$ (200)	(279)	$ (250)
Net of tax	12		12
Accumulated Net Unrealized Investment Gain (Loss) Attributable to Parent [Member] \| Reclassification out of Accumulated Other Comprehensive Income [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Realized gains on sale of securities,Other income	12		12
Income tax benefit	$ 0		$ 0

Fair Value Measurements - Summary of Financial Assets Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Financial assets
Restricted cash	$ 1,469	$ 700
Recurring [Member]
Financial assets
Total financial assets	72,889	107,441
Recurring [Member] \| US Government Corporations and Agencies Securities [Member]
Financial assets
Available-for-sale marketable securities	8,890	13,496
Recurring [Member] \| Corporate Bonds [Member]
Financial assets
Available-for-sale marketable securities	15,051	14,188
Recurring [Member] \| Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Financial assets
Total financial assets	6,895	15,801
Recurring [Member] \| Significant Other Observable Inputs (Level 2) [Member]
Financial assets
Total financial assets	65,994	91,640
Recurring [Member] \| Significant Other Observable Inputs (Level 2) [Member] \| US Government Corporations and Agencies Securities [Member]
Financial assets
Available-for-sale marketable securities	8,890	13,496
Recurring [Member] \| Significant Other Observable Inputs (Level 2) [Member] \| Corporate Bonds [Member]
Financial assets
Available-for-sale marketable securities	15,051	14,188
Recurring [Member] \| Money Market Mutual Funds [Member]
Financial assets
Cash and cash equivalents	5,426	15,101
Available-for-sale marketable securities	18,877	41,986
Recurring [Member] \| Money Market Mutual Funds [Member] \| Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Financial assets
Cash and cash equivalents	5,426	15,101
Recurring [Member] \| Money Market Mutual Funds [Member] \| Significant Other Observable Inputs (Level 2) [Member]
Financial assets
Available-for-sale marketable securities	18,877	41,986
Recurring [Member] \| U.S. Treasury Securities [Member]
Financial assets
Available-for-sale marketable securities	2,502	2,528
Recurring [Member] \| U.S. Treasury Securities [Member] \| Significant Other Observable Inputs (Level 2) [Member]
Financial assets
Available-for-sale marketable securities	2,502	2,528
Recurring [Member] \| Commercial Paper [Member]
Financial assets
Available-for-sale marketable securities	20,674	19,442
Recurring [Member] \| Commercial Paper [Member] \| Significant Other Observable Inputs (Level 2) [Member]
Financial assets
Available-for-sale marketable securities	20,674	19,442
Recurring [Member] \| Commercial Money Market Account [Member]
Financial assets
Restricted cash	1,469
Recurring [Member] \| Commercial Money Market Account [Member] \| Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Financial assets
Restricted cash	$ 1,469
Recurring [Member] \| Bank Certificate of Deposit [Member]
Financial assets
Restricted cash		700
Recurring [Member] \| Bank Certificate of Deposit [Member] \| Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Financial assets
Restricted cash		$ 700

Fair Value Measurements - Additional Information (Detail)	9 Months Ended
	Sep. 30, 2016 USD ($)
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Purchases of financial assets	$ 0
Sales of financial assets	0
Maturities of financial assets	0
Transfer of financial asset into level 3 of fair value	0
Fair value assets level 2 to level 1 transfers	0
Fair value assets level 1 to level 2 transfers	0
Significant Unobservable Inputs (Level 3) [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Unrealized gains	0
Unrealized losses	$ 0

Restricted Cash - Additional Information (Detail) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted cash balance	$ 1,469	$ 700
Shelton Lease [Member]
Restricted Cash and Cash Equivalents Items [Line Items]
Restricted cash balance	$ 700
Lease term	2017-10
Stamford Lease [Member]
Restricted Cash and Cash Equivalents Items [Line Items]
Lease term	2023-10
Letter of credit, remaining amount	$ 769
Letter of credit, remaining amount after three years	$ 408

Prepaid Expenses - Additional Information (Detail) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid expenses	$ 4,820	$ 1,729
Prepaid R&D clinical costs	4,363	1,500
Prepaid insurance	327	98
Other prepaid costs	$ 130	35
Prepaid rent		$ 96

Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Detail) - USD ($) $ in Thousands	Sep. 30, 2016	Dec. 31, 2015
Payables and Accruals [Abstract]
Accounts payable	$ 2,387	$ 1,965
Accrued research projects	1,817	1,542
Accrued Shelton lease liability	998
Accrued professional fees	373	371
Accrued compensation and benefits	1,177	1,204
Accrued other	73	186
Total	$ 6,825	$ 5,268

Stockholders' Equity - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands		9 Months Ended
	Aug. 04, 2015	Sep. 30, 2015	Sep. 30, 2016	Dec. 31, 2015	Jul. 29, 2015
Subsidiary, Sale of Stock [Line Items]
Common stock, shares issued			27,282,863	27,254,863
Follow On Public Offering [Member]
Subsidiary, Sale of Stock [Line Items]
Common stock, shares issued					3,763,440
Net proceeds from offering of common stock	$ 75,231	$ 75,231
Follow On Public Offering [Member] \| Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Stock issued	3,763,440	4,327,956
Public offering price per share	$ 18.60	$ 18.6
Net proceeds from offering of common stock		$ 4
Follow On Public Offering [Member] \| Underwriter's Over-Allotment [Member] \| Maximum [Member]
Subsidiary, Sale of Stock [Line Items]
Common stock, shares issued	564,516

Collaborations - Additional Information (Detail) $ in Thousands	1 Months Ended		3 Months Ended		9 Months Ended
	Sep. 30, 2015 USD ($)	Apr. 30, 2013 USD ($)	Sep. 30, 2016 USD ($)	Sep. 30, 2015 USD ($)	Sep. 30, 2016 USD ($) Deliverables	Sep. 30, 2015 USD ($)	Apr. 30, 2012 USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
License and milestone fee revenue				$ 1,710		$ 1,710
Withholding tax			$ (55)	(200)	$ (279)	(250)
Collaborative revenue				730		2,093
Chong Kun Dang Pharmaceutical Corporation [Member] \| KOREA, REPUBLIC OF
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Withholding tax						124
Withholding tax due	$ 83			83		83
Maruishi Pharmaceutical Co., Ltd. [Member] \| JAPAN
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Contractual foreign currency exchange adjustments	275
Chong Kun Dang Agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential milestone payments receivable							$ 3,750
License and milestone fee revenue						626
Milestone payment receivable	417			417		417
Chong Kun Dang Agreement [Member] \| Clinical Development [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential milestone payments receivable							2,250
Chong Kun Dang Agreement [Member] \| Regulatory Events [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Potential milestone payments receivable							$ 1,500
Maruishi Agreement [Member]
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
License and milestone fee revenue				1,084		1,084
Number of deliverables for revenue recognized \| Deliverables					2
Upfront non-refundable, non-creditable license fee		$ 15,000
Deferred R&D service revenue				89		1,452
Revenue recognized from non-substantive milestones					$ 8,000
Revenue recognized from substantive milestones					$ 2,500
Full amount of milestone payment received	$ 1,725
Collaborative revenue				641		641
Clinical trial costs related to the R&D services deliverable				$ 108		$ 1,583

Net Loss Per Share - Computation of Denominators Used in Net Loss per Share (Detail) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Basic:
Weighted average common shares outstanding	27,282,863	25,545,164	27,275,133	23,737,443
Diluted:
Weighted average common shares outstanding - Basic	27,282,863	25,545,164	27,275,133	23,737,443
Common stock options	0	0	0	0
Denominator for diluted net loss per share	27,282,863	25,545,164	27,275,133	23,737,443

Net Loss Per Share - Computation of Basic and Diluted Net Loss per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Earnings Per Share [Abstract]
Net loss	$ (11,542)	$ (4,787)	$ (35,308)	$ (15,160)
Weighted-average common shares outstanding:
Basic and Diluted	27,282,863	25,545,164	27,275,133	23,737,443
Net loss per share, Basic and Diluted	$ (0.42)	$ (0.19)	$ (1.29)	$ (0.64)

Net Loss Per Share - Additional Information (Detail) - shares	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Employee Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common stock equivalents	2,299,117	1,541,772

Stock-Based Compensation - Additional Information (Detail) - USD ($)		3 Months Ended		9 Months Ended
	Jan. 01, 2016	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Excess tax benefits reported in cash flows from operations				$ 0	$ 0
Excess tax benefits reported in cash flows from financing activities				$ 0	$ 0
Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Fair value of options granted		$ 3.92	$ 13.30	$ 3.81	$ 6.60
Nonemployee Consultants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average fair values of outstanding options		$ 5.75	$ 10.87	$ 4.16	$ 9.03
2014 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock options that may be granted after the tenth anniversary of the 2014 Plan				0
Annual increases in number of shares reserved for issuance as a percentage of shares of capital stock outstanding through January 1, 2024				3.00%
Share-based compensation arrangement by share-based payment award, number of shares authorized	3,101,707					2,284,061
Options granted		75,000	25,000	797,000	629,000
2014 Equity Incentive Plan [Member] \| Share-Based Compensation Award, Tranche One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of vested shares on first anniversary of grant date				25.00%
2014 Equity Incentive Plan [Member] \| Share-based Compensation Award, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period of awards granted				36 months
2014 Equity Incentive Plan [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Term of awards granted				10 years
2014 Equity Incentive Plan [Member] \| Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period of awards granted	4 years
2014 Equity Incentive Plan [Member] \| Incentive Stock Options [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, number of shares authorized		30,000,000		30,000,000

Stock-Based Compensation - Summary of Assumptions Used in Black-Scholes Option Pricing Model (Detail)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	1.19%	1.77%
Risk-free interest rate, minimum			1.19%	1.43%
Risk-free interest rate, maximum			1.79%	1.89%
Expected volatility	71.90%	64.10%
Expected volatility, minimum			67.80%	64.00%
Expected volatility, maximum			72.60%	67.10%
Expected dividend yield	0.00%	0.00%	0.00%	0.00%
Employee Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life of options (in years)	6 years 3 months	6 years 3 months	6 years 3 months	6 years 3 months
Nonemployee Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life of options (in years)	0 years	0 years	10 years	10 years

Stock-Based Compensation - Summary of Compensation Expense Relating to Stock Options (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock option expense	$ 777	$ 661	$ 1,971	$ 1,807
Research and Development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock option expense	375	283	867	761
General and Administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock option expense	$ 402	$ 378	$ 1,104	$ 1,046

Stock-Based Compensation - Summary of Stock Option Award Activity (Detail) - 2014 Equity Incentive Plan [Member] - $ / shares	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Outstanding, at December 31, 2015			1,658,408
Number of Shares, Granted	75,000	25,000	797,000	629,000
Number of Shares, Exercised			(28,000)
Number of shares, Forfeited			(95,792)
Number of shares, Expired			(32,499)
Number of Shares, Outstanding, September 30, 2016	2,299,117		2,299,117
Number of Shares, Options exercisable, September 30, 2016	887,213		887,213
Weighted-Average Exercise Price, Outstanding, at December 31, 2015			$ 10.27
Weighted-Average Exercise Price, Granted			5.99
Weighted-Average Exercise Price, Exercised			1.41
Weighted-Average Exercise Price, Forfeited			12.15
Weighted-Average Exercise Price, Expired			11.03
Weighted Average Exercise Price, Outstanding, September 30, 2016	$ 8.80		8.80
Weighted Average Exercise Price, Options exercisable, September 30, 2016	$ 8.98		$ 8.98

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Income Tax Disclosure [Abstract]
Pre-tax losses	$ (11,597)	$ (4,987)	$ (35,587)	$ (15,410)
Benefit from income taxes	$ (55)	$ (200)	$ (279)	$ (250)
Percentage of annual research and development credit for cash			65.00%

Commitments and Contingencies - Schedule of Contractual Obligations and Commitments (Detail) $ in Thousands	Sep. 30, 2016 USD ($)
Operating Leased Assets [Line Items]
2016	$ 425
2017	1,615
2018	1,093
2019	1,217
2020	1,241
Thereafter	3,650
Total	9,241
Stamford Operating Lease [Member]
Operating Leased Assets [Line Items]
2016	192
2017	875
2018	1,093
2019	1,217
2020	1,241
Thereafter	3,650
Total	8,268
Shelton Operating Lease [Member]
Operating Leased Assets [Line Items]
2016	232
2017	740
Total	$ 972

Commitments and Contingencies - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended	9 Months Ended
	May 31, 2016	Sep. 30, 2016	Sep. 30, 2016	Dec. 31, 2015
Other Commitments [Line Items]
Net book value of leasehold improvements		$ 1,665	$ 1,665	$ 1,263
Lease minimum rental payment		9,241	9,241
Restructuring liability		998	998
Stamford Operating Lease [Member]
Other Commitments [Line Items]
Tenant improvement expenses		1,094	1,094
Lease minimum rental payment		8,268	8,268
Stamford Operating Lease [Member] \| Leasehold Improvements [Member]
Other Commitments [Line Items]
Amortization of deferred lease obligation		36	71
Shelton Operating Lease [Member]
Other Commitments [Line Items]
Additional amortization expense			$ 899
Additional loss per share			$ 0.03
Accrued cease use date liability	$ 1,312		$ 1,312
Accumulated deferred lease obligation, written off	$ 429
Lease minimum rental payment		972	972
Restructuring liability		998	998	$ 0
Shelton Operating Lease [Member] \| Leasehold Improvements [Member]
Other Commitments [Line Items]
Net book value of leasehold improvements		$ 0	$ 0

Commitments and Contingencies - Schedule of Reconciliation of Balances of Accrued Shelton Lease Cease-Use Liability (Detail) - USD ($) $ in Thousands		9 Months Ended
	May 31, 2016	Sep. 30, 2016
Restructuring Cost and Reserve [Line Items]
Balance, September 30, 2016		$ 998
Shelton Operating Lease [Member]
Restructuring Cost and Reserve [Line Items]
Balance, January 1, 2016		0
Additional accruals	$ 1,312	1,312
Rental payments		(314)
Balance, September 30, 2016		$ 998